TRIM32 — TRIM32, tripartite motif containing 32

The TRIM32 gene provides instructions for making a protein that acts as an E3 ubiquitin ligase, a type of enzyme that helps tag other proteins for degradation or modification. This tagging process is essential for maintaining the health and function of various cells, particularly in muscle tissue and the brain. The TRIM32 protein is involved in muscle regeneration, cell growth, and maintaining the structural integrity of muscle fibers. When the TRIM32 gene is mutated, the protein it produces may not function correctly or may be unstable. This disruption can lead to a buildup of damaged proteins or a failure to properly regulate cellular processes. In patients, these mutations most commonly cause Limb-girdle muscular dystrophy R8 (LGMD R8) or Sarcotubular myopathy (STM), which are characterized by progressive muscle weakness. Interestingly, specific mutations in a different part of the gene can cause Bardet-Biedl syndrome 11 (BBS11), a condition that affects multiple body systems, including the retina, leading to vision loss. For patients and families, understanding the specific mutation in the TRIM32 gene is important because it determines the type of condition they may develop. Both LGMD R8 and BBS11 are inherited in an autosomal recessive pattern, meaning an individual must inherit two mutated copies of the gene (one from each parent) to develop the disease. Genetic counseling can help families understand the risks and implications of these conditions.

Gene description: Encodes an E3 ubiquitin ligase involved in protein degradation and muscle differentiation.

Patient and family guide: The TRIM32 gene provides instructions for making a protein that acts as an E3 ubiquitin ligase, a type of enzyme that helps tag other proteins for degradation or modification. This tagging process is essential for maintaining the health and function of various cells, particularly in muscle tissue and the brain. The TRIM32 protein is involved in muscle regeneration, cell growth, and maintaining the structural integrity of muscle fibers. When the TRIM32 gene is mutated, the protein it produces may not function correctly or may be unstable. This disruption can lead to a buildup of damaged proteins or a failure to properly regulate cellular processes. In patients, these mutations most commonly cause Limb-girdle muscular dystrophy R8 (LGMD R8) or Sarcotubular myopathy (STM), which are characterized by progressive muscle weakness. Interestingly, specific mutations in a different part of the gene can cause Bardet-Biedl syndrome 11 (BBS11), a condition that affects multiple body systems, including the retina, leading to vision loss. For patients and families, understanding the specific mutation in the TRIM32 gene is important because it determines the type of condition they may develop. Both LGMD R8 and BBS11 are inherited in an autosomal recessive pattern, meaning an individual must inherit two mutated copies of the gene (one from each parent) to develop the disease. Genetic counseling can help families understand the risks and implications of these conditions.

Gene function: TRIM32 acts as an E3 ubiquitin ligase, regulating protein turnover and cellular processes. In the retina, it is involved in maintaining photoreceptor integrity and function. Mutations disrupt this balance, leading to the accumulation of misfolded proteins and subsequent photoreceptor degeneration.

Protein structure: The TRIM32 gene encodes a protein of 653 amino acids that belongs to the tripartite motif (TRIM) family. The N-terminal region of the protein contains a characteristic RING finger domain, a single B-box domain (Type II), and a coiled-coil region. The RING domain coordinates two zinc ions and is essential for the protein's E3 ubiquitin ligase catalytic activity, as well as mediating dimerization. The B-box and coiled-coil domains are involved in proper protein folding and the formation of higher-order complexes, such as tetramers. The C-terminal region of TRIM32 consists of six NHL (NCL-1, HT2A, LIN-41) repeats. These repeats fold into a beta-propeller structure, where each repeat forms four antiparallel beta sheets arranged toroidally around a central axis. The NHL domains are crucial for mediating protein-protein interactions and providing substrate specificity. Mutations in the NHL domains typically lead to muscular dystrophies, while mutations in the B-box domain are associated with Bardet-Biedl syndrome.

Molecular function: TRIM32 functions primarily as an E3 ubiquitin ligase within the ubiquitin-proteasome system. It is responsible for transferring ubiquitin molecules to specific target proteins, tagging them either for degradation by the 26S proteasome or for other cellular fates such as altered trafficking or stabilization. TRIM32 can append both K48-linked and K63-linked polyubiquitin chains, and it also has the ability to monoubiquitinate certain substrates. Additionally, TRIM32 can undergo autoubiquitination. In skeletal muscle, TRIM32 targets several key structural and regulatory proteins, including actin, tropomyosin, desmin, and dysbindin. It plays a critical role in muscle homeostasis, regulating the balance between protein synthesis and degradation during muscle atrophy and regeneration. TRIM32 is involved in the insulin/PI3K/Akt/FoxO signaling pathway, where it modulates the activity of PI3K to influence muscle growth and wasting. Furthermore, TRIM32 is essential for maintaining the stability of costameres, which are protein complexes that link the muscle contractile apparatus to the sarcolemma. Beyond muscle tissue, TRIM32 is involved in neural stem cell differentiation, innate immunity, and tumor suppression. It ubiquitinates cell cycle regulators and oncogenes such as c-Myc, MYCN, and p53, thereby controlling cell proliferation. In the context of Bardet-Biedl syndrome, TRIM32 interacts with other BBS proteins, suggesting a role in ciliary function and intracellular transport, which is critical for the survival and function of photoreceptor cells in the retina.

Expression pattern: TRIM32 is a ubiquitous protein that is expressed in a wide variety of tissues throughout the human body. It shows particularly robust expression in skeletal muscle, where it localizes to the Z-disc and the M-line of myofibrils, as well as to costameres at the sarcolemma. Elevated levels of TRIM32 expression are also found in the brain and the heart, indicating its importance in neural and cardiac tissues. During development, TRIM32 is expressed in embryonic musculature and plays a role in neural stem cell differentiation. In the context of the retina, while TRIM32 is ubiquitously expressed, its specific role in photoreceptor cells is highlighted by its association with Bardet-Biedl syndrome (BBS11), a condition characterized by pigmentary retinopathy. The protein's involvement in ciliary function suggests it is expressed and active in ciliated cells, including retinal photoreceptors.

Mutation spectrum: The mutation spectrum of the TRIM32 gene includes missense mutations, frameshifts, insertions, and large deletions. The vast majority of pathogenic variants associated with Limb-girdle muscular dystrophy R8 (LGMD R8) and Sarcotubular myopathy (STM) are clustered within the C-terminal NHL repeat domains. The most common mutation is a founder mutation, p.Asp487Asn (c.1459G>A), located in the third NHL repeat, which is highly prevalent in the Hutterite population of North America. Other notable NHL domain mutations include p.Arg394His, p.Val591Met, and p.His567Arg. In contrast, mutations that cause Bardet-Biedl syndrome 11 (BBS11) are typically located in the B-box domain of the protein, such as the p.Pro130Ser missense mutation. This distinct spatial distribution of mutations correlates with the divergent clinical phenotypes. While over 10 pathogenic variants have been reported, LGMD R8 remains an extremely rare disorder, with fewer than 100 patients documented worldwide outside of the Hutterite isolate.

Pathogenic variants: 1. p.Asp487Asn (c.1459G>A) - The most common founder mutation in the Hutterite population, located in the NHL domain. It causes both Limb-girdle muscular dystrophy R8 and Sarcotubular myopathy. 2. p.Arg394His (c.1181G>A) - A well-characterized missense mutation in the NHL domain that destabilizes the protein and causes LGMD R8. 3. p.Pro130Ser (c.388C>T) - A missense mutation located in the B-box domain that is responsible for Bardet-Biedl syndrome 11 (BBS11), a pleiotropic disorder including retinal dystrophy. 4. p.Val591Met (c.1771G>A) - A missense mutation in the fourth NHL repeat associated with LGMD R8, leading to reduced protein levels and increased autophagic flux. 5. p.His567Arg (c.1700A>G) - A novel missense mutation in the NHL domain that interferes with the self-association of the TRIM32 protein, causing LGMD R8.

Clinical significance: Mutations in the TRIM32 gene manifest clinically as two distinct autosomal recessive disorders depending on the location of the mutation. Mutations in the NHL domains cause Limb-girdle muscular dystrophy R8 (LGMD R8) and Sarcotubular myopathy (STM). LGMD R8 is characterized by slowly progressive proximal muscle weakness, atrophic wasting of the lower extremities, and mild to moderate elevation of creatine kinase (CK) levels. The age of onset typically ranges from the second to third decade of life, and patients may remain ambulatory into their sixth decade. STM is considered a subtle variant of LGMD R8, generally presenting with an earlier onset in childhood and more severe muscle weakness. Conversely, mutations in the B-box domain of TRIM32 cause Bardet-Biedl syndrome 11 (BBS11). BBS11 is a pleiotropic disorder characterized by pigmentary retinopathy (leading to vision loss), obesity, polydactyly, renal abnormalities, learning disabilities, and hypogonadism. Unlike LGMD R8, BBS11 does not typically present with primary muscle pathology, highlighting the diverse functional roles of the TRIM32 protein in different tissues.

Inheritance: Autosomal Recessive

Chromosomal location: 9q33.1

Genotype-phenotype correlations: There is a strong genotype-phenotype correlation associated with the TRIM32 gene based on the specific protein domain affected by the mutation. Pathogenic variants located in the C-terminal NHL repeat domains consistently result in primary myopathies, specifically Limb-girdle muscular dystrophy R8 (LGMD R8) and Sarcotubular myopathy (STM). These mutations often destabilize the NHL beta-propeller structure, impairing the protein's ability to self-associate or interact with muscle-specific substrates. On the other hand, mutations located in the N-terminal B-box domain, such as p.Pro130Ser, lead to Bardet-Biedl syndrome 11 (BBS11). This suggests that the B-box domain is critical for interactions with other BBS proteins or for functions related to cilia maintenance, which are essential for retinal and renal health. Furthermore, within the LGMD R8 spectrum, patients carrying two mutations in the NHL repeats tend to have an earlier disease onset and more severe symptoms, and there is evidence that female patients may experience less severe symptoms than males, although symptoms can exacerbate during pregnancy.

Research and therapeutic approaches: Currently, there are no approved targeted therapies or cures for TRIM32-related disorders, including LGMD R8 and BBS11. Management is primarily supportive and focuses on alleviating symptoms and improving the patient's quality of life. For LGMD R8, this includes physical and occupational therapy to maintain muscle function and joint mobility, the use of assistive devices, and monitoring for respiratory or cardiac complications. For BBS11, management involves treating the specific manifestations, such as weight management for obesity, educational support, and low-vision aids for retinal dystrophy. In terms of pipeline therapies, gene therapy holds promise for inherited retinal diseases and muscular dystrophies. While there are no active clinical trials specifically testing gene replacement for TRIM32, preclinical research using viral vectors (such as AAV) to deliver functional copies of genes has shown success in other forms of LGMD and retinal dystrophies (e.g., Luxturna for RPE65-associated retinal dystrophy). Future therapeutic strategies for TRIM32 may involve AAV-mediated gene transfer to restore E3 ubiquitin ligase function in muscle and retinal tissues, or the development of small molecules that can stabilize mutant TRIM32 proteins.

Diagnostic testing: Diagnosis of TRIM32-related disorders relies on clinical evaluation, muscle biopsy (for LGMD R8/STM), and molecular genetic testing. Genetic testing is typically performed using next-generation sequencing (NGS) multigene panels that include TRIM32 and other genes associated with limb-girdle muscular dystrophies or Bardet-Biedl syndrome. If panel testing is inconclusive, whole exome sequencing (WES) or whole genome sequencing (WGS) may be utilized to identify rare point mutations or large deletions, such as the 43 kb deletion that removes the entire TRIM32 gene. Genetic counseling is a critical component of the diagnostic process. Because TRIM32-related disorders are inherited in an autosomal recessive manner, parents of an affected individual are obligate carriers and have a 25% chance of having another affected child in subsequent pregnancies. Counselors can provide information on carrier testing for at-risk family members and discuss options for prenatal diagnosis or preimplantation genetic testing.

Animal models: Several animal models have been developed to study the function of TRIM32 and the pathogenesis of its associated diseases. The TRIM32 knockout (KO) mouse model exhibits impaired muscle strength, reduced muscle weight, and myopathic features such as centralized nuclei, fiber splitting, and a dilated sarcotubular system, closely mimicking human LGMD R8 and STM. Interestingly, these mice also display a neurogenic phenotype with reduced myelinated axon diameter, suggesting a role for TRIM32 in the nervous system. A TRIM32 knock-in (KI) mouse model carrying the human p.Asp487Asn mutation also presents with mild myopathic and neurogenic phenotypes, along with reduced TRIM32 protein levels. In addition to murine models, the fruit fly (Drosophila melanogaster) has been used extensively. The 'thin' (tn) mutant, which lacks the Drosophila ortholog of TRIM32, shows progressive muscle degeneration, abnormal sarcomeric patterning, and locomotor deficits. This model has been crucial for demonstrating that all domains of TRIM32 are required for normal muscle function and costamere stability. Zebrafish knockdown models have also been utilized to demonstrate the role of TRIM32 in muscle development and function.

Population genetics: TRIM32-related disorders are extremely rare in the general population. However, the p.Asp487Asn (c.1459G>A) mutation exhibits a strong founder effect in the Hutterite population of North America (specifically in Manitoba, Canada). In this genetic isolate, the carrier frequency for the p.Asp487Asn mutation is exceptionally high, estimated at approximately 1 in 6.5 individuals. Outside of the Hutterite community, pathogenic variants in TRIM32 are exceedingly uncommon, and the global carrier frequency is very low, contributing to the rarity of LGMD R8 and BBS11 worldwide.

Selected references: 1. Bawa S, Piccirillo R, Geisbrecht ER. TRIM32: A Multifunctional Protein Involved in Muscle Homeostasis, Glucose Metabolism, and Tumorigenesis. Biomolecules, 2021. PMID: 33802079 2. Guan Y, Liang X, Li W, et al. TRIM32 biallelic defects cause limb-girdle muscular dystrophy R8: identification of two novel mutations and investigation of genotype-phenotype correlation. Skeletal Muscle, 2023. PMID: 37217984 3. Kudryashova E, Wu J, Havton LA, Spencer MJ. Deficiency of the E3 ubiquitin ligase TRIM32 in mice leads to a myopathy with a neurogenic component. Hum Mol Genet, 2009. PMID: 19429910 4. Chiang AP, Beck JS, Yen HJ, et al. Homozygosity mapping with SNP arrays identifies TRIM32, an E3 ubiquitin ligase, as a Bardet-Biedl syndrome gene (BBS11). Proc Natl Acad Sci U S A, 2006. PMID: 16606853 5. Schoser BG, Frosk P, Engel AG, et al. Commonality of TRIM32 mutation in causing sarcotubular myopathy and LGMD2H. Ann Neurol, 2005. PMID: 15732099 6. Frosk P, Weiler T, Nylen E, et al. Limb-girdle muscular dystrophy type 2H associated with mutation in TRIM32, a putative E3-ubiquitin-ligase gene. Am J Hum Genet, 2002. PMID: 11822024